Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Canan G. Nebigil"'
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 11 (2023)
Introduction: Annexin A2 (AnxA2) plays a critical role in cell transformation, immune response, and resistance to cancer therapy. Besides functioning as a calcium- and lipidbinding protein, AnxA2 also acts as an mRNA-binding protein, for instance, by
Externí odkaz:
https://doaj.org/article/3362a26f2401430d93c5c6cc26c9ad4a
Editorial: HF2Cancer: Exploring bidirectional interaction between cardiovascular diseases and cancer
Autor:
Canan G. Nebigil, Michael W. Y. Chan
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
Externí odkaz:
https://doaj.org/article/895d788557894e1488fa0abf1ea6f773
Autor:
Melisa N. Guler, Nathalie M. Tscheiller, Maria Sabater-Molina, Juan R. Gimeno, Canan G. Nebigil
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
Heart failure (HF) and cancer are responsible for 50% of all deaths in middle-aged people. These diseases are tightly linked, which is supported by recent epidemiological studies and case control studies, demonstrating that HF patients have a higher
Externí odkaz:
https://doaj.org/article/67a885ffb30d4a369fbac4f49a5caab5
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Vascular toxicity is a frequent adverse effect of current anticancer chemotherapies and often results from endothelial dysfunction. Vascular endothelial growth factor inhibitors (VEGFi), anthracyclines, plant alkaloids, alkylating agents, antimetabol
Externí odkaz:
https://doaj.org/article/301b3f1481424122a413a8fc03876d92
Autor:
Adeline Gasser, PhD, Yu-Wen Chen, MD, PhD, Anais Audebrand, MSci, Ayhan Daglayan, MSci, Marine Charavin, PhD, Brigitte Escoubet, MD, PhD, Pavel Karpov, PhD, Igor Tetko, PhD, Michael W.Y. Chan, PhD, Daniela Cardinale, MD, PhD, Laurent Désaubry, PhD, Canan G. Nebigil, PharmD, PhD
Publikováno v:
JACC. CardioOncology, Vol 1, Iss 1, Pp 84-102 (2019)
Objectives: This study investigated how different concentrations of doxorubicin (DOX) can affect the function of cardiac cells. This study also examined whether activation of prokineticin receptor (PKR)-1 by a nonpeptide agonist, IS20, prevents DOX-i
Externí odkaz:
https://doaj.org/article/084a7eda97e34e36bf013fb6c4afb797
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 7 (2020)
Externí odkaz:
https://doaj.org/article/a4ea9da82b514c729aa531095f0c9961
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 6 (2020)
Novel anticancer medicines, including targeted therapies and immune checkpoint inhibitors, have greatly improved the management of cancers. However, both conventional and new anticancer treatments induce cardiac adverse effects, which remain a critic
Externí odkaz:
https://doaj.org/article/8b66bc79a5cc4fc5b8061529cd5cbece
Publikováno v:
Journal of Developmental Biology, Vol 8, Iss 4, p 32 (2020)
The authors wish to make the following corrections to this paper [...]
Externí odkaz:
https://doaj.org/article/ec6a97a9785940ac808642ac4bcaf5e3
Autor:
Canan G. Nebigil, Laurent Désaubry
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Cardiotoxicity is one of the main adverse effects of chemotheraphy, affecting the completion of cancer therapies and the short- and long-term quality of life. Anthracyclines are currently used to treat many cancers, including the various forms of leu
Externí odkaz:
https://doaj.org/article/6aead2cb68ba4457993a8e3fd2030966
Autor:
Nora Chouha, Hussein Abou-Hamdan, Hajime Yurugi, Riku Yoshii, Hiromi Ii, Ahmad Najem, Ghanem E. Ghanem, Susumu Nakata, Krishnaraj Rajalingam, Yu Peng, Dong Wang, Canan G. Nebigil, Laurent Désaubry
Publikováno v:
European Journal of Medicinal Chemistry
European Journal of Medicinal Chemistry, 2022, 242, pp.114635. ⟨10.1016/j.ejmech.2022.114635⟩
European Journal of Medicinal Chemistry, 2022, 242, pp.114635. ⟨10.1016/j.ejmech.2022.114635⟩
Fluorizoline is a cytotoxic trifluorothiazoline that targets the scaffold proteins prohibitins-1 and -2 (PHB1/2) to inhibit the kinase C-RAF and promote the expression of the cyclin-dependent kinase inhibitor p21 to induce cancer cell death. In melan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cc9b51a7fa505ea1d0e6306f4d0fe36
https://hal.science/hal-03806694
https://hal.science/hal-03806694
